Anti-Human CD20 Recombinant Antibody (Rituximab) product vial
Creative Biolabs
Biosimilar of Rituximab (Rituxan)

Anti-Human CD20 Recombinant Antibody (Rituximab)

Catalog TAB-016Target: CD20 (MS4A1)

Rituximab is a chimeric monoclonal antibody against the protein CD20, primarily expressed on B cells. Rituximab destroys B cells and is used to treat diseases characterised by excessive, overactive or dysfunctional B cells, including many lymphomas, leukaemias, transplant rejection and autoimmune disorders.

View on creativebiolabs.net
Compare 3 alternatives from other suppliers
Specifications

Specs at a glance

Target
CD20 (MS4A1)
Clonality
Monoclonal
Host species
Mouse
Isotype
IgG1, kappa
Reactivity
Human
Format
Chimeric (mouse/human) antibody; IgG format
Derivation
Chimeric (mouse/human)
Immunogen
Human lymphoblastoid cell line SB
Specificity
Tested positive against native human antigen
Validated applications
NeutralisationELISAIFIPFunctional AssayFlow CytometryWB

Purity

>97% (SDS-PAGE). Molecular weight 143,859.7 g/mol. Biological half-life 30 to 400 hours.

Storage

Store at -20°C or lower upon receiving. Avoid repeated freeze-thaw cycles.

Therapeutic identifiers

The drug behind the biosimilar

Database identifiers for the approved therapeutic this product is a biosimilar of.

Generic name
Rituximab
Trade name
rituximab
CAS
174722-31-7
ATC code
L01XC02
Molecular weight
143,859.7 g/mol
DrugBank
DB00073
ChEMBL
CHEMBL1201576
UNII
4F4X42SYQ6

Approved indication

Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA), in combination with glucocorticoids.

Validation

Western blot, IHC and flow cytometry images

Validation images supplied by Creative Biolabs will appear here. Independent validation evidence is also surfaced via PubMed citations below.

Use cases

What researchers use this for

  • CD20 cell studies
  • Flow cytometry analysis
  • Immunoassays
  • Lymphoblastoid research
FAQ

Questions about TAB-016

Is the anti-Human CD20 therapeutic antibody Rituximab suitable for use in flow cytometry analysis?

Yes, the anti-Human CD20 therapeutic antibody Rituximab (TAB-016) is suitable for use in flow cytometry analysis. It provides specific binding to CD20, allowing for the detection of CD20-expressing cells in flow cytometry assays.

What are the storage recommendations for the anti-Human CD20 therapeutic antibody Rituximab?

The recommended storage condition for the anti-Human CD20 therapeutic antibody Rituximab (TAB-016) is at -20°C or lower. For short-term storage, it can be kept at 2-8°C. To ensure stability, avoid repeated freeze-thaw cycles.

Can the anti-Human CD20 therapeutic antibody Rituximab be used in immunoprecipitation assays?

Yes, the anti-Human CD20 therapeutic antibody Rituximab (TAB-016) can be used in immunoprecipitation assays. It provides specific binding to CD20, enabling the successful precipitation of the target protein from complex mixtures.

Is the anti-Human CD20 therapeutic antibody Rituximab effective in ELISA applications?

Yes, the anti-Human CD20 therapeutic antibody Rituximab (TAB-016) is effective in ELISA applications. It has been validated for use in such assays and provides reliable detection of CD20.

What is the optimal dilution for using the anti-Human CD20 therapeutic antibody Rituximab in immunofluorescence?

The optimal dilution for using the anti-Human CD20 therapeutic antibody Rituximab (TAB-016) in immunofluorescence is typically 1:100 to 1:500. It is advisable to perform a dilution series to determine the best working concentration for your specific experimental conditions.
Procurement

Request a quote for TAB-016

BioLynkr enquiries are answered within one business day.

Email
info@creative-biolabs.com
Phone
1-631-357-2254 / 1-631-416-1478